Literature DB >> 25844357

De novo malignancy after liver transplantation: a single-center experience of 14 cases.

Peng Ji Gao1, Jie Gao1, Zhao Li1, Zhi Ping Hu1, Ji Ye Zhu1.   

Abstract

PURPOSE: The aim of this study is to evaluate the incidence of de novo malignancy after liver transplantation (LT) and compare with those among the general Chinese population.
METHODS: A total of 466 patients who had a minimum follow-up time of 6 months were enrolled in the study. All data of medical records and follow up were retrospectively reviewed.
RESULTS: The incidence rate of de novo malignancy was 3.0% (14 in 466 patients). The median elapsed time from transplant to the diagnosis of de novo malignancy was 42 months (range, 6 to 106 months). The cumulative risk for development of de novo malignancy was 1.6%, 2.7%, and 8.2% at 3, 5 and 10 years after LT, respectively. The patients were all male. The types of de novo tumors included digestive system tumor (8 in 14), lung cancer (2 in 14), urologic neoplasm (2 in 14), and hematologic malignant tumor (2 in 14). Over a mean follow-up of 24 months after diagnosis of de novo malignancy, 7 patients (50.0%) died; the overall 5-year patient survival rate was 54.5%. The relative risk of malignancy following LT was 9.5 folds higher than the general Chinese population.
CONCLUSION: The relative risk of malignancy following LT was much higher than the general Chinese population. Digestive system tumor is the most common type of de novo malignancy after LT in China.

Entities:  

Keywords:  Incidence; Liver transplantation; Neoplasms; Transplant recipients

Year:  2015        PMID: 25844357      PMCID: PMC4384282          DOI: 10.4174/astr.2015.88.4.222

Source DB:  PubMed          Journal:  Ann Surg Treat Res        ISSN: 2288-6575            Impact factor:   1.859


  22 in total

1.  De novo cancer after orthotopic liver transplantation.

Authors:  V Peyrègne; C Ducerf; M Adham; E de la Roche; N Berthoux; B Bancel; T Bizollon; J Baulieux
Journal:  Transplant Proc       Date:  1998-06       Impact factor: 1.066

2.  Skin cancer and other cutaneous disorders in liver transplant recipients.

Authors:  Anna Belloni-Fortina; Stefano Piaserico; Matteo Bordignon; Martina Gambato; Marco Senzolo; Francesco Paolo Russo; Andrea Peserico; Giuseppe De Matteis; Egle Perissinotto; Umberto Cillo; Alessandro Vitale; Mauro Alaibac; Patrizia Burra
Journal:  Acta Derm Venereol       Date:  2012-07       Impact factor: 4.437

3.  Evolution and management of de novo neoplasm post-liver transplantation: a 20-year experience from a single European centre.

Authors:  Gonzalo Sapisochin; Itxarone Bilbao; Cristina Dopazo; Luis Castells; Jose Luis Lázaro; Roberto Rodríguez; Mireia Caralt; Laia Blanco; Joaquin Balsells; Ramón Charco
Journal:  Hepatol Int       Date:  2010-12-28       Impact factor: 6.047

4.  The current management of hepatoblastoma: a combination of chemotherapy, conventional resection, and liver transplantation.

Authors:  Gregory M Tiao; Nicola Bobey; Steven Allen; Neris Nieves; Maria Alonso; John Bucuvalas; Robert Wells; Frederick Ryckman
Journal:  J Pediatr       Date:  2005-02       Impact factor: 4.406

5.  De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry.

Authors:  H W Park; S Hwang; C S Ahn; K H Kim; D B Moon; T Y Ha; G W Song; D H Jung; G C Park; J M Namgoong; S Y Yoon; C S Park; Y H Park; H J Lee; S G Lee
Journal:  Transplant Proc       Date:  2012-04       Impact factor: 1.066

6.  Cancers of new appearance in liver transplant recipients: incidence and evolution.

Authors:  M E Romero-Vargas; M Flores-Cortés; Z Valera; M A Gómez-Bravo; L Barrera-Pulido; F Pareja-Ciuró; J Serrano Díez-Canedo; I García; A Bernardos
Journal:  Transplant Proc       Date:  2006-10       Impact factor: 1.066

7.  Report of incidence and mortality in China cancer registries, 2009.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Guanglin Li; Lingyou Wu; Jie He
Journal:  Chin J Cancer Res       Date:  2013-02       Impact factor: 5.087

8.  Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.

Authors:  Stephen L Guthery; James E Heubi; John C Bucuvalas; Thomas G Gross; Frederick C Ryckman; Maria H Alonso; William F Balistreri; Richard W Hornung
Journal:  Transplantation       Date:  2003-04-15       Impact factor: 4.939

9.  De novo posttransplantation nonlymphoproliferative malignancies in liver transplant recipients.

Authors:  I Boin; M I Leonardi; R B Stucchi; E C Ataide; J R Almeida; R H Barros; L S Leonardi
Journal:  Transplant Proc       Date:  2007-12       Impact factor: 1.066

10.  The paracholedochal vein: a feasible option as portal inflow in living donor liver transplantation.

Authors:  Joo Dong Kim; Dong Lak Choi; Young Seok Han
Journal:  Ann Surg Treat Res       Date:  2014-06-24       Impact factor: 1.859

View more
  3 in total

1.  De Novo Malignancy After Living Donor Liver Transplantation: A Large Volume Experience.

Authors:  Anisha Tiwari; Sanjiv Saigal; Narendra S Choudhary; Sujeet Saha; Amit Rastogi; Prashant Bhangui; Neeraj Saraf; Thiagrajan Srinivasan; Sanjay K Yadav; Dheeraj Gautam; Samiran Nundy; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2020-02-13

2.  Current Challenges in the Post-Transplant Care of Liver Transplant Recipients in Germany.

Authors:  Kerstin Herzer; Martina Sterneck; Martin-Walter Welker; Silvio Nadalin; Gabriele Kirchner; Felix Braun; Christina Malessa; Adam Herber; Johann Pratschke; Karl Heinz Weiss; Elmar Jaeckel; Frank Tacke
Journal:  J Clin Med       Date:  2020-11-05       Impact factor: 4.241

Review 3.  Extrahepatic Malignancies and Liver Transplantation: Current Status.

Authors:  Narendra S Choudhary; Sanjiv Saigal; Neeraj Saraf; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2020-10-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.